Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36

Benzinga · 1d ago
Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $45 to $36.